EUCTR2008-003185-26-IT进行中（未招募）不适用
Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK) cells after allogeneic stem cell transplantation - CIK 2
AZIENDA OSPEDALIERA OSPEDALI RIUNITI DI BERGAMO (A.O. DI RILIEVO NAZIONALE)0 个研究点开始时间: 2008年10月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with haematologic malignancies (excluding CML) with a molecular, cytogenetic or haematologic relapse after allogeneic transplantation (therapeutic schedule).
- • Patients with haematologic malignancies at high risk of relapse or progression after allogeneic BMT because being not in complete remission at time of conditioning regimen (prophylactic schedule).
- • Patients with an available donor willing to donate peripheral blood lymphocytes or patients transplanted with a Cord Blood Unit from which CIK cells could have been prepared at time of transplantation (immediately after thawing of the Cord Blood Unit).
- • Patients must give written informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- • Donors positive for HIV, HBV or HCV, or unfit to undergo leukapheresis
- • Patients with active acute or chronic GvHD
- • Positive pregnancy test of female patients and use of reliable contraceptive methods for patients of both genders.
- • Patients with severe psychiatric illness or any disorder that compromises ability to give truly informed consent for participation in this study
研究者
相似试验
进行中（未招募）
不适用
A phase I-II study: infusion of donor lymphocytes transduced with the suicide gene HSV TK, after transplantation of allogeneic T-depleted stem cells from a haploidentical donor in patients with haematological malignancies - TK007Hematological malignancies at high risk of relapse based on disease progression or presence of negative prognostic factor, who have received a HCTfrom donor HLA mismatched (haploidentical) for 2 or 3 loci.EUCTR2005-003587-34-GRMolMed70
招募中
不适用
Consolidative donor lymphocyte infusion following HLA-mismatched allogeneic hematopoietic stem cell transplantation from haploidentical donor for hematological malignancy in non-remission.JPRN-UMIN000043766Division of Hematology, Jichi Medical University Saitama Medical Center24
已完成
1 期
Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene for therapy-resistant esophageal cancerJPRN-UMIN000002395Mie University Hospital9
已完成
1 期
Adoptive transfer of lymphocytes transduced with MAGE-A4-specific TCR gene following lymphodepleting conditioning for therapy-resistant esophageal cancerTherapy-resistant esophageal cancerJPRN-UMIN000010729Department of Immuno-gene Therapy, Mie University Graduate School of Medicine12
招募中
3 期
se of stem cells which have capacity to grow to liver cells in patients of cirrhosis of liver who have jaundice, ascites( water in abdomen)CTRI/2017/11/010429Asian Healthcare Foundation